Insider Selling: Inogen Inc (INGN) EVP Sells 27,630 Shares of Stock

Inogen Inc (NASDAQ:INGN) EVP Alison Bauerlein sold 27,630 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $116.46, for a total value of $3,217,789.80. Following the transaction, the executive vice president now owns 11,718 shares of the company’s stock, valued at $1,364,678.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Alison Bauerlein also recently made the following trade(s):

  • On Friday, February 9th, Alison Bauerlein sold 11,718 shares of Inogen stock. The stock was sold at an average price of $115.87, for a total value of $1,357,764.66.

Inogen Inc (NASDAQ INGN) traded up $0.49 during trading on Tuesday, reaching $117.90. The company had a trading volume of 123,377 shares, compared to its average volume of 133,449. Inogen Inc has a twelve month low of $66.51 and a twelve month high of $130.05. The stock has a market capitalization of $2,460.00, a PE ratio of 82.45, a price-to-earnings-growth ratio of 3.96 and a beta of 1.02.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its stake in Inogen by 4.0% during the fourth quarter. BlackRock Inc. now owns 2,306,534 shares of the medical technology company’s stock worth $274,662,000 after purchasing an additional 87,737 shares during the last quarter. Vanguard Group Inc. lifted its stake in Inogen by 24.9% during the second quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock worth $144,594,000 after purchasing an additional 301,737 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Inogen by 3.4% during the second quarter. Dimensional Fund Advisors LP now owns 519,523 shares of the medical technology company’s stock worth $49,572,000 after purchasing an additional 17,111 shares during the last quarter. State Street Corp lifted its stake in Inogen by 6.8% during the second quarter. State Street Corp now owns 425,662 shares of the medical technology company’s stock worth $40,619,000 after purchasing an additional 27,250 shares during the last quarter. Finally, FMR LLC lifted its stake in Inogen by 3.8% during the second quarter. FMR LLC now owns 336,424 shares of the medical technology company’s stock worth $32,102,000 after purchasing an additional 12,224 shares during the last quarter.

Several equities analysts recently commented on INGN shares. Needham & Company LLC boosted their target price on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, November 8th. Leerink Swann restated an “outperform” rating and set a $120.00 target price (up from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $131.00 target price for the company in a research report on Thursday, November 9th. Finally, BidaskClub cut Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday, December 5th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Inogen has a consensus rating of “Buy” and an average target price of $103.14.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Inogen Inc (INGN) EVP Sells 27,630 Shares of Stock” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/13/insider-selling-inogen-inc-ingn-evp-sells-27630-shares-of-stock.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply